Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine E Varley

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Nature Communications|December 9, 2021
A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancerYanli Liu, Zhong Wu, Jin Zhou, et al.
Cell Reports|August 9, 2018
Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland DevelopmentRajshekhar R Giraddi, Chi-Yeh Chung, Richard E Heinz, et al.
Breast Cancer Research : BCR|February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerChristos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Oncotarget|December 29, 2016
Genomic regulation of invasion by STAT3 in triple negative breast cancerJoy M McDaniel, Katherine E Varley, Jason Gertz, et al.
Blood|November 15, 2021
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosisHelong Zhao, Anthony D Pomicter, Anna M Eiring, et al.
Clinical and Translational Medicine|December 19, 2022
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolismMayra A Gonzalez, Idaly M Olivas, Alfonso E Bencomo-Alvarez, et al.
Nature Cancer|February 28, 2022
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncologyKatrin P Guillen, Maihi Fujita, Andrew J Butterfield, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Nature Communications|December 9, 2021
A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancerYanli Liu, Zhong Wu, Jin Zhou, et al.
Cell Reports|August 9, 2018
Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland DevelopmentRajshekhar R Giraddi, Chi-Yeh Chung, Richard E Heinz, et al.
Breast Cancer Research : BCR|February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerChristos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Oncotarget|December 29, 2016
Genomic regulation of invasion by STAT3 in triple negative breast cancerJoy M McDaniel, Katherine E Varley, Jason Gertz, et al.
Blood|November 15, 2021
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosisHelong Zhao, Anthony D Pomicter, Anna M Eiring, et al.
Clinical and Translational Medicine|December 19, 2022
Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolismMayra A Gonzalez, Idaly M Olivas, Alfonso E Bencomo-Alvarez, et al.
Nature Cancer|February 28, 2022
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncologyKatrin P Guillen, Maihi Fujita, Andrew J Butterfield, et al.
Pageof 4